Summary & Overview
HCPCS C1897: Lead, Neurostimulator Test Kit (Implantable)
HCPCS Level II code C1897 identifies an implantable neurostimulator test lead used during trial stimulation to evaluate patient response prior to permanent neurostimulator implantation. This code matters nationally because trial-phase neurostimulation is a common step in managing refractory chronic pain and certain movement disorders; appropriate coding ensures accurate itemization of implantable components and supports clinical decision-making and payment clarity.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise review of coverage patterns and practical benchmarks where available, highlights coding context for device trial procedures, and summarizes the clinical role of test leads in neurostimulation trials.
Readers will learn the clinical context for using a test-phase implantable lead, the typical sites of service for placement, and which major payers and Medicare commonly address coding and coverage for neurostimulation trials. When payer-specific policy text or reimbursement benchmarks are not provided in the input, the report indicates that certain data elements are not available. The focus is national in scope and intended for billing, clinical, and policy stakeholders who manage or oversee neuromodulation services.
Billing Code Overview
HCPCS Level II code C1897 describes a Lead, neurostimulator test kit (implantable). This item represents an implantable test lead component used during the trial phase of neurostimulation therapy to assess therapeutic response before permanent device implantation.
Service Type: Implantable neurostimulator lead for test/trial use
Typical Site of Service: Inpatient or outpatient surgical settings, ambulatory surgical centers, or specialized pain management procedure suites
Clinical & Coding Specifications
Clinical Context
A patient with chronic, refractory neuropathic pain (for example, failed back surgery syndrome or complex regional pain syndrome) is referred for a temporary neurostimulation trial to determine responsiveness before permanent device implantation. The patient is typically evaluated in a pain management clinic by an interventional pain specialist or neurosurgeon. Pre-procedure steps include a focused history, medication review (anticoagulants and antibiotics addressed per facility policy), informed consent, and baseline pain scores. The procedure is often performed in an outpatient ambulatory surgery center or hospital procedure room with monitored anesthesia care or light sedation depending on patient comorbidity.
During the implantation of a trial lead, the clinician inserts one or more C1897 leads (neurostimulator test kit, implantable) percutaneously under fluoroscopic guidance into the epidural or peripheral nerve target. Intra-procedural testing confirms paresthesia coverage or appropriate neuromodulation parameters. The lead(s) are externalized and connected to an external pulse generator for a trial period (typically 3–14 days). The patient returns for trial follow-up to assess pain relief and functional improvement. If successful, the trial lead information guides selection and placement of permanent leads and an implantable pulse generator in a subsequent procedure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |